latest news releases from the newsroom
Wireless Ronin Technologies, Inc.
Wireless Ronin Reports 2006 Fourth Quarter and Full Year Results
MINNEAPOLIS, Feb. 16, 2007 (PRIME NEWSWIRE) -- Wireless Ronin Technologies, Inc. (Nasdaq:RNIN) today announced its financial results for the 2006 fourth quarter and full year. The company reported revenue of $1.2 million for the fourth quarter of 2006, in comparison to $0.2 million during the fourth quarter of 2005, a net loss of $8.5 million compared to a net loss of $1.5 million last year, and a basic and diluted loss per share of $2.33 compared to $1.98 last year. The increase in net loss for the 2006 fourth quarter was primarily attributable to increased operating costs as well as higher interest expense. The greater amount of interest expense was due to higher debt levels, the early retirement of long- and short-term debt and the recording of additional beneficial conversion during the period. The majority of the interest expense was non-cash. The increase in basic and diluted loss per share was primarily due to the increase in interest expense and operating costs, reduced by the increase in shares outstanding. Fourth-quarter results also include costs of approximately $166,000 after-tax, or $0.05 per basic and diluted share, of non-cash stock option expense related to FAS123R. The company adopted FAS123R for reporting purposes in the first quarter of 2006.
Pan American Silver Corp.
Pan American Silver Proven and Probable Reserves Up 20 Percent, 35.4 Million Ounces Added
VANCOUVER, British Columbia, Feb. 16, 2007 (PRIME NEWSWIRE) -- Pan American Silver Corp. (Nasdaq:PAAS) (TSX:PAA) is pleased to announce the results of its 2006 year-end reserve and resource evaluation. In addition to replacing 100% of reserves mined during 2006, the Company added a further 20%, or 35.4 million ounces of silver, to its proven and probable reserves. At the Company's operating and development properties, measured and indicated resources increased 12.1 million ounces, while inferred resources grew by 9.9 million ounces.
OrthoLogic Announces Results of Post Hoc Subgroup Analysis of Data From Phase 3 Clinical Trial of Chrysalin (TP508) in Fracture Repair
SAN DIEGO, Feb. 16, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced findings of a post hoc subgroup analysis of data from its Phase 3 clinical trial of the novel synthetic peptide Chrysalin(R) (TP508) in unstable, displaced distal radius (wrist) fractures. Within the subset of female osteopenic subjects, treatment with 10 mcg Chrysalin demonstrated a statistically significant benefit compared to placebo in the primary efficacy endpoint of time to removal of immobilization. Secondary endpoints including clinical assessment of fracture healing (pain or motion at the fracture site), time to radial cortical bridging and time to overall radiographic healing also showed a significant effect of Chrysalin treatment.